These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

407 related items for PubMed ID: 28637104

  • 1. [Treatment Options in Non-alcoholic Fatty Liver Disease].
    Kim W.
    Korean J Gastroenterol; 2017 Jun 25; 69(6):353-358. PubMed ID: 28637104
    [Abstract] [Full Text] [Related]

  • 2. Elafibranor, an Agonist of the Peroxisome Proliferator-Activated Receptor-α and -δ, Induces Resolution of Nonalcoholic Steatohepatitis Without Fibrosis Worsening.
    Ratziu V, Harrison SA, Francque S, Bedossa P, Lehert P, Serfaty L, Romero-Gomez M, Boursier J, Abdelmalek M, Caldwell S, Drenth J, Anstee QM, Hum D, Hanf R, Roudot A, Megnien S, Staels B, Sanyal A, GOLDEN-505 Investigator Study Group.
    Gastroenterology; 2016 May 25; 150(5):1147-1159.e5. PubMed ID: 26874076
    [Abstract] [Full Text] [Related]

  • 3. Elafibranor: a potential drug for the treatment of nonalcoholic steatohepatitis (NASH).
    Westerouen Van Meeteren MJ, Drenth JPH, Tjwa ETTL.
    Expert Opin Investig Drugs; 2020 Feb 25; 29(2):117-123. PubMed ID: 31523999
    [Abstract] [Full Text] [Related]

  • 4. Emerging Treatments for Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis.
    Gawrieh S, Chalasani N.
    Clin Liver Dis; 2018 Feb 25; 22(1):189-199. PubMed ID: 29128056
    [Abstract] [Full Text] [Related]

  • 5. Current and upcoming pharmacotherapy for non-alcoholic fatty liver disease.
    Rotman Y, Sanyal AJ.
    Gut; 2017 Jan 25; 66(1):180-190. PubMed ID: 27646933
    [Abstract] [Full Text] [Related]

  • 6. Emerging role of obeticholic acid in the management of nonalcoholic fatty liver disease.
    Makri E, Cholongitas E, Tziomalos K.
    World J Gastroenterol; 2016 Nov 07; 22(41):9039-9043. PubMed ID: 27895393
    [Abstract] [Full Text] [Related]

  • 7. Reversal of NASH fibrosis with pharmacotherapy.
    Alukal JJ, Thuluvath PJ.
    Hepatol Int; 2019 Sep 07; 13(5):534-545. PubMed ID: 31363910
    [Abstract] [Full Text] [Related]

  • 8. Hepatoprotective effects of the dual peroxisome proliferator-activated receptor alpha/delta agonist, GFT505, in rodent models of nonalcoholic fatty liver disease/nonalcoholic steatohepatitis.
    Staels B, Rubenstrunk A, Noel B, Rigou G, Delataille P, Millatt LJ, Baron M, Lucas A, Tailleux A, Hum DW, Ratziu V, Cariou B, Hanf R.
    Hepatology; 2013 Dec 07; 58(6):1941-52. PubMed ID: 23703580
    [Abstract] [Full Text] [Related]

  • 9. miR-21 ablation and obeticholic acid ameliorate nonalcoholic steatohepatitis in mice.
    Rodrigues PM, Afonso MB, Simão AL, Carvalho CC, Trindade A, Duarte A, Borralho PM, Machado MV, Cortez-Pinto H, Rodrigues CM, Castro RE.
    Cell Death Dis; 2017 Apr 13; 8(4):e2748. PubMed ID: 28406477
    [Abstract] [Full Text] [Related]

  • 10. The therapeutic landscape of non-alcoholic steatohepatitis.
    Perazzo H, Dufour JF.
    Liver Int; 2017 May 13; 37(5):634-647. PubMed ID: 27727520
    [Abstract] [Full Text] [Related]

  • 11. Metabolic and hepatic effects of liraglutide, obeticholic acid and elafibranor in diet-induced obese mouse models of biopsy-confirmed nonalcoholic steatohepatitis.
    Tølbøl KS, Kristiansen MN, Hansen HH, Veidal SS, Rigbolt KT, Gillum MP, Jelsing J, Vrang N, Feigh M.
    World J Gastroenterol; 2018 Jan 14; 24(2):179-194. PubMed ID: 29375204
    [Abstract] [Full Text] [Related]

  • 12. Emerging Therapies for Nonalcoholic Fatty Liver Disease.
    Hameed B, Terrault N.
    Clin Liver Dis; 2016 May 14; 20(2):365-85. PubMed ID: 27063275
    [Abstract] [Full Text] [Related]

  • 13. Farnesoid X receptor targeting to treat nonalcoholic steatohepatitis.
    Adorini L, Pruzanski M, Shapiro D.
    Drug Discov Today; 2012 Sep 14; 17(17-18):988-97. PubMed ID: 22652341
    [Abstract] [Full Text] [Related]

  • 14. Efficacy and safety of the farnesoid X receptor agonist obeticholic acid in patients with type 2 diabetes and nonalcoholic fatty liver disease.
    Mudaliar S, Henry RR, Sanyal AJ, Morrow L, Marschall HU, Kipnes M, Adorini L, Sciacca CI, Clopton P, Castelloe E, Dillon P, Pruzanski M, Shapiro D.
    Gastroenterology; 2013 Sep 14; 145(3):574-82.e1. PubMed ID: 23727264
    [Abstract] [Full Text] [Related]

  • 15. Farnesoid X nuclear receptor agonists for the treatment of nonalcoholic steatohepatitis.
    Venetsanaki V, Karabouta Z, Polyzos SA.
    Eur J Pharmacol; 2019 Nov 15; 863():172661. PubMed ID: 31536725
    [Abstract] [Full Text] [Related]

  • 16. Combined obeticholic acid and elafibranor treatment promotes additive liver histological improvements in a diet-induced ob/ob mouse model of biopsy-confirmed NASH.
    Roth JD, Veidal SS, Fensholdt LKD, Rigbolt KTG, Papazyan R, Nielsen JC, Feigh M, Vrang N, Young M, Jelsing J, Adorini L, Hansen HH.
    Sci Rep; 2019 Jun 21; 9(1):9046. PubMed ID: 31227742
    [Abstract] [Full Text] [Related]

  • 17. [Treatment of non-alcoholic fatty liver disease].
    Heebøll S, Vilstrup H, Grønbæk H.
    Ugeskr Laeger; 2018 Jul 30; 180(31):. PubMed ID: 30064623
    [Abstract] [Full Text] [Related]

  • 18. Current treatment options for nonalcoholic fatty liver disease.
    Shetty A, Syn WK.
    Curr Opin Gastroenterol; 2019 May 30; 35(3):168-176. PubMed ID: 30844893
    [Abstract] [Full Text] [Related]

  • 19. Nuclear control of inflammation and fibrosis in nonalcoholic steatohepatitis: therapeutic potential of dual peroxisome proliferator-activated receptor alpha/delta agonism.
    Quintero P, Arrese M.
    Hepatology; 2013 Dec 30; 58(6):1881-4. PubMed ID: 23787705
    [No Abstract] [Full Text] [Related]

  • 20. A dual farnesoid X receptor/soluble epoxide hydrolase modulator treats non-alcoholic steatohepatitis in mice.
    Hye Khan MA, Schmidt J, Stavniichuk A, Imig JD, Merk D.
    Biochem Pharmacol; 2019 Aug 30; 166():212-221. PubMed ID: 31129048
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 21.